Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01641575 · ClinicalTrials.gov registry record · Phase 1
A Dose Ascending Study of Gemcitabine Elaidate (CO-101) in Combination With Cisplatin
A Phase 1 study, sponsored by Clovis Oncology.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT01641575: Clinical Trial Phase 1 study, sponsored by Clovis Oncology.
NCT01641575 is a Phase 1 study that was terminated before completion, run by Clovis Oncology. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01641575, a Phase 1 study, was terminated before completion, sponsored by Clovis Oncology.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of the first part of the study is to evaluate the safety, tolerability, and pharmacokinetics of ascending doses of gemcitabine elaidate in combination with cisplatin given to patients with advanced solid tumors, and to select a dose for further evaluation in the second part of the study. The purpose of the second part of the study is to determine the safety, tolerability, and exploratory clinical activity of gemcitabine elaidate in combination with cisplatin given to patients with Stage IIIb/IV non-small-cell lung cancer (NSCLC).
Interventions
- DRUG CO-1.01 and Cisplatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2012-07 |
| Est. Completion | 2013-06 |
| Phase | Phase 1 |
Why NCT01641575 stopped before completion
NCT01641575 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 1 intervention - of which CO-1.01 and Cisplatin is the first listed.
NCT01641575 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01641575 about?
NCT01641575 is a clinical study titled "A Dose Ascending Study of Gemcitabine Elaidate (CO-101) in Combination With Cisplatin". The purpose of the first part of the study is to evaluate the safety, tolerability, and pharmacokinetics of ascending doses of gemcitabine elaidate in combination with cisplatin given to patients with advanced solid tumors, and to select a dose for further evaluation in the second part of the study....
What is the current status of trial NCT01641575?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2012-07. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01641575?
The interventions under investigation include: CO-1.01 and Cisplatin (DRUG).
Who is sponsoring clinical trial NCT01641575?
This trial is sponsored by Clovis Oncology, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01641575's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia